Mode of action of the antitumor compound girodazole (RP 49532A, NSC 627434)

Biochem Pharmacol. 1992 Apr 15;43(8):1717-23. doi: 10.1016/0006-2952(92)90701-j.

Abstract

Girodazole (RP 49532A) or 3-amino-1-[4-(2 amino-1H-imidazolyl]-propanol, 2HCl is an experimental antitumor compound which inhibits protein synthesis in cell cultures and in cell free systems. The compound has been evaluated for its capacity to inhibit specific assays of initiation, elongation and termination of protein synthesis. Girodazole inhibited the release of nascent peptides from polyribosomes in rabbit reticulocyte lysates indicating that the major effect of the compound is on the protein synthesis termination step.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • Glaucarubin / analogs & derivatives
  • Glaucarubin / pharmacology
  • Globins / biosynthesis
  • Imidazoles / pharmacology*
  • Peptide Chain Elongation, Translational / drug effects*
  • Peptide Chain Termination, Translational / drug effects*
  • Polyribosomes / drug effects
  • Polyribosomes / metabolism
  • Propanolamines / pharmacology*
  • Protein Biosynthesis*
  • Quassins*
  • Rabbits
  • Reticulocytes / drug effects
  • Reticulocytes / metabolism
  • Trichothecenes / pharmacology

Substances

  • Antineoplastic Agents
  • Imidazoles
  • Propanolamines
  • Quassins
  • Trichothecenes
  • girodazole
  • Globins
  • Glaucarubin
  • bruceantin
  • diacetoxyscirpenol